Wanbury Approves Whole-Time Director Re-Appointment and Cost Auditor
Wanbury Ltd 路 Change in Management 路 25 Sept 2026, 1:47 am
Wanbury Approves Whole-Time Director Re-Appointment and Cost Auditor Wanbury Limited announced that shareholders approved key resolutions at its 38th AGM on 24th Sep'26. The company approved the re-appointment and continuation of Mohan Kumar Rayana as Whole-time Director beyond age 70 for a five-year term from 21st Aug'26 to 20th Aug'31. Additionally, shareholders approved the appointment and remuneration of M/s. ABK & Associates, Cost Accountants, as Cost Auditor for FY27. Rayana holds over 25 years of advisory experience with Wanbury, overseeing business strategy, general management, fund raising, and debt settlement.
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Disclosure under Regulation 30 of the SEBI LODR, 2015 - Investors Presentation on Q2 and Half Year ended 30.09.2026. 路 18 Nov 2026
- Clarifications on investor queries regarding recent announcement 路 16 Nov 2026
- Wanbury Limited''s Tanuku Plant - US FDA Inspection - Updates 路 16 Nov 2026
- Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HC1 EP grade. 路 12 Nov 2026
- Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026. 路 06 Nov 2026
- Financial Results as on 30th September, 2026 路 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 路 05 Nov 2026
- Wanbury Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
